Resources
Full text of IRA- HHS Report on Out of Pocket Spending Projected Under the IRA
- HHS has adds 25 drugs to its list of products eligible for Inflation Reduction Act rebates. Under the Inflation Reduction Act (IRA), drug companies must pay rebates to Medicare when their prescription drug prices increase faster than the rate of inflation. Please check page 2 for any rare cancer treatments.
- HHS’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) released findings that the IRA’s changes to the Medicare Part D program may reduce out-of-pocket spending by nearly $400 for more than 18.7 million enrollees when the provisions are implemented in 2025, or about one in three people with Medicare Part D. Among this population, which we suspect includes rare cancer patients, given our higher out-of-pocket costs, the report finds nearly 1.9 million enrollees are projected to save at least $1,000 in 2025.
- HHS’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) released a report for the anniversary of the enactment of the Inflation Reduction Act. The report features key findings from the first year of implementing IRA Medicare Provisions.
- NORD Position Paper and Sign-on Letter on IRA
- Everylife Foundation Primer on IRA
- ACSCAN Webinar on IRA Basics
- No Patient Left Behind – “Value of Medicines”, “Small Molecule R&D Parity”, “Left Behind Sign On Letter“
- Partnership For Health Analytic Research: Implications of the Inflation Reduction Act Price Setting Provisions on Post-approval Indications for Small Molecule Medicines
- Vital Transformations – “Build Back Better Act – Total Market Impact Of Price Controls In Medicate Parts D & B”
- Price comparisons with other OECD countries
Helpful Articles
- Pink Sheet – “Underwater: Medicare Negotiated Prices For Part B Cancer Drugs Could Change Prescribing” (October 2023)
- Pink Sheet – Summary of Court Cases
- Kaiser Family Foundation – “Changes to Medicare Part D in 2024 and 2025 Under the Inflation Reduction Act and How Enrollees Will Benefit” (April 2023)
- PoliticoPro – “CMS adopts light touch with insurers covering negotiated drugs” (October 2023)
- Pink Sheet – “As Medicare Drug Negotiation Patient Sessions Kick Off, Advocates Already Eyeing Improvements” (October 2023)
- Pink Sheet – “Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session” (October 2023)
- Washington Examiner – “White House compares public’s slow embrace of Inflation Reduction Act to Obamacare” Neera Tanden, White House Domestic Policy Council Director, told reporters that the Inflation Reduction Act will be appreciated in time, as was the Affordable Care Act. (August 2023)
- STAT News – “How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’” (October 2022)
- Endpoints News – “One year later: The upsides and downsides of the Inflation Reduction Act” (August 2023)